Article

Australian agency Oks wet AMD treatment

Hunenberg, Switzerland—The Australian Therapeutics Goods Administration has approved Alcon Inc.'s anecortave acetate suspension 15 mg (RETAANE) for the treatment of subfoveal choroidal neovascularization caused by exudative age-related macular degeneration (wet AMD) where there is a classic component.

Hunenberg, Switzerland-The Australian Therapeutics Goods Administration has approved Alcon Inc.'s anecortave acetate suspension 15 mg (RETAANE) for the treatment of subfoveal choroidal neovascularization caused by exudative age-related macular degeneration (wet AMD) where there is a classic component.

The company said it would continue its efforts to gain approval in the United States, Europe, Canada, South Africa, New Zealand, and Switzerland.

It also said it has executed a clinical trial agreement with the National Eye Institute (NEI) to provide the drug for an NEI study of wet AMD. The multicenter, randomized, prospective trial will research the long-term safety and efficacy of the drug in patients with all forms of wet AMD who are undergoing intravitreal bevacizumab (Avastin, Genentech Inc., South San Francisco, CA) therapy.

Meanwhile, Jacqualyn Fouse, Alcon's senior vice president, finance, and chief financial officer (CFO), was named Financial Executive of the Year by Robert Half International and the Institute of Management Accountants. Fouse is the second woman to receive the national award in its 9-year history, and the second recipient from the health-care industry. She has been Alcon's CFO since 2002.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.